The National Comprehensive Cancer Network added a prostate cancer test, IsoPSA, to its guidelines for early detection of the disease.
The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company.Â
